TauroLock™ is more cost-efficient than 4 % citrate.
Comparison of our TauroLock™ 2+1 protocol (TauroLock™-Hep500 twice weekly and TauroLock™-U25.000 once weekly) versus 4 % citrate.
The study was performed as a prospective, multicenter, randomized, controlled trial in hemodialysis patients using newly inserted tunneled central venous catheters (in total 15,690 catheter days).
0.67 vs. 2.7/1000 catheter days in 4 % citrate group (p=0.003).
18.7 vs. 44.3/1000 catheter days in 4 % citrate group (p=0.001).
Significantly more frequent use of alteplase rescue in the citrate group (9.8 vs. 3.8/1000 catheter days, p=0.001).
43 % of overall expenses per patient and year.
TauroLock™ 2+1 was significantly superior regarding all catheter-related aspects (infection prevention and function) and even cut expenses to half of those with 4 % citrate.